Mar 27, 2019
What is the endocannabinoid system?
By Jeff G. Konin

You have heard of the endocrine system. The digestive system. The circulatory, respiratory, and nervous systems of the body. Have you ever heard of the endocannabinoid system (ECS) of the body? Most anatomy and physiology books identify 12 distinct human body systems, of which the ECS is not one of. In fact, surveys show that only 13% of medical schools teach about the ECS. Furthermore, an even greater number of physicians and other health care providers practicing today were not formally trained about the ECS.

To be fair, the ECS was only discovered in the 1990s.

Illustration: Beth Scupham

We have known about the ECS for about 25 years. It was first discovered in the 1990s by Lisa Matsuda at the National Institute of Mental Health. Dr. Matsuda first described the structure and functional expression of the cannabinoid receptor, CB-1. It turns out that the ECS is comprised of a complex network of cannabinoid receptors located throughout the central and peripheral nervous system. Since then, other cannabinoid receptors, specifically CB-2 found in the immune and digestive system, and many of the major organs, have been discovered.

What does it mean to us that the body has another system with its own receptors? To be honest, we still don’t know exactly how the ECS works. However, what we are learning is that when the system does not work, it effects important physiological functions and an individual’s ability to maintain a homeostatic life. Specifically, an improper functioning ECS can impact sleep, appetite, pain, inflammation, memory, mood and reproduction.

   » ALSO SEE: Makings Gains on Pain: The evolution of pain management

Fun fact: All animals have an ECS. Patient testimonials reveal improvement from a multitude of diseases — cancer, neurodegenerative disorders, rheumatoid arthritis, migraines, fibromyalgia — after trying some form of endocannabinoids. There’s actually a name for the condition when the ECS is not working as it should: Clinical Endocannabinoid System Deficiency Syndrome.

Imagine that the cannabis plant contains CB-1 and CB-2, acting as a supplement to what one normal body would produce within the ECS. This can be thought of in a similar way to that of the endocrine system. When the body does not produce insulin to break down blood sugar, adverse symptoms seen with diabetes appear. A patient who is unable to regulate blood sugar levels through daily diet and exercise may need to inject insulin. A body that does not produce adequate amounts of CB-1 and CB-2 may find therapeutic effects from CB-1 and CB-2 found in the hemp plant.

While we lack an abundance of randomized clinical trials and evidence to support the early anecdotal reports and clinical theories, there is something to this that deserves further exploration. We have always been taught to listen to our patients. There is no better time than now to do this, as our patients are not waiting for scientific evidence to find relief for their ailments.

CannaInsider has more about the endocannabinoid system and the research on how cannabis interacts with this system.

Dr. Jeff G. Konin is the Vice President for Global Education and Research at AIB in Largo, Florida and President of Konin Consulting, LLC in Clearwater Florida. He is a frequent speaker on various topics related to cannabis.for healthcare providers, student-athletes, educators, and administrators.

Shop see all »

75 Applewood Drive, Suite A
P.O. Box 128
Sparta, MI 49345
website development by deyo designs
Interested in receiving the print or digital edition of Training & Conditioning?

Subscribe Today »

Be sure to check out our sister sites: